Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ib/II Study of ALT-803 in Combination With Gemcitabine and Nab-paclitaxel in Patients With Advanced Pancreatic Cancer

NCT02559674 is registered in ClinicalTrials.gov with Altor BioScience as lead sponsor.

NCT NCT02559674
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02559674 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ib/II Study of ALT-803 in Combination With Gemcitabine and Nab-paclitaxel in Patients With Advanced Pancreatic Cancer
Lead sponsor
Altor BioScience
Phase
Phase 1
Overall status
Completed
Start date
July 31, 2016
Completion date
February 21, 2018
Enrollment
8 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced pancreatic cancer